Company news
Hubei Jumpcan Pharmaceutical Co., Ltd news in 2025
Hubei Jumpcan Pharmaceutical Co., Ltd's news releases, calls and decks from 2025, newest first.
Announcement on Shareholding of Top 10 Shareholders and Top 10 Holders of Shares Without Sales Limit Concerning Shares Repurchase
December 1, 2025
Announcement on Resolutions of the 19th Meeting of the 10th Board of Directors
November 24, 2025
Announcement on Implementation of Repurchase and Cancellation of Partial Restricted Stocks under 2022 Restricted Stock and Stock Option Incentive Plan
November 21, 2025
湖北济川药业股份有限公司关于全资子公司开立募集资金现金管理专用结算账户并利用闲置募集资金进行现金管理的进展公告
November 18, 2025
Announcement on Progress in Wholly-owned Subsidiaries Opening Special Settlement Account for Cash Management of Raised Funds and Using Idle Raised Funds for Cash Management
November 11, 2025
Report for Q3 2025
October 27, 2025
Announcement on Implementation of Independent Exercise in the 1st Exercise Period of Initially Granted Stock Options in 2022 Restricted Stock and Stock Option Incentive Plan
October 9, 2025
Announcement on Lifting Trading Restrictions and Listing of the 1st Trade Restriction Release Period of Initially Granted Restricted Stock under the 2022 Restricted Stock and Stock Option Incentive Plan
September 24, 2025
Announcement on Convening the 2025 Semi-annual Performance Briefing
September 23, 2025
Announcement on Resignation of Non-independent Director and Election of Employee Representative Director
September 19, 2025
Announcement on Obtaining Drug Registration Certificate by Subsidiary
September 16, 2025
Announcement on the Release of Pledge for Shares Held by the Controlling Shareholder
September 15, 2025
Indicative Announcement on Convening the 1st Extraordinary General Meeting in 2025
September 12, 2025
Indicative Announcement on the Use of Self-exercise for the 1st Exercise Period of Stock Options of Initial Grant under the 2022 Restricted Stock and Stock Option Incentive Plan
September 9, 2025
Announcement on Progress in Wholly-Owned Subsidiary’s Utilization of Idle Raised Capital for Cash Management, Redemption at Maturity, and Continued Cash Management
September 3, 2025
Announcement on Resolutions of the 16th Meeting of the 10th Board of Directors
August 22, 2025
Announcement on the Completion of Cancellation of Some Stock Options under the 2022 Restricted Stock and Stock Option Incentive Plan
August 7, 2025
Announcement on Completion of Share Delivery for Mr. Cao Fei's Tender Offer to Acquire the Company's Shares
July 31, 2025
Announcement on Release of Pledge of Partial Shares of Controlling Shareholders
July 21, 2025
Announcement on the Obtaining of the Drug Registration Certificate for the Collaborative Product Masiloxavir Tablets
July 20, 2025